This study will examine the safety profile of SGN-CD70A. The study will test increasing doses
of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to
small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given
to patients without causing unacceptable side effects. The pharmacokinetics and antitumor
activity of SGN-CD70A will also be evaluated.